DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
L-Lysine is an investigational drug.
There have been 16 clinical trials for L-Lysine. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2002.
The most common disease conditions in clinical trials are Carcinoma, Syndrome, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Roswell Park Cancer Institute, and Genmedica Therapeutics S.L.
Recent Clinical Trials for L-Lysine
|Radio-immunotherapy (CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC) for the Treatment of Unresectable or Metastatic Breast Cancer Patients||Roswell Park Cancer Institute||Phase 1|
|Reparixin in COVID-19 Pneumonia - Multicentre Study on the Efficacy and Safety||Dompé Farmaceutici S.p.A||Phase 2/Phase 3|
|Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma||Merck Sharp & Dohme Corp.||Phase 1|